Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Get Free Report)’s share price dropped 1.4% on Tuesday . The company traded as low as $3.47 and last traded at $3.50. Approximately 25,652 shares changed hands during trading, a decline of 6% from the average daily volume of 27,263 shares. The stock had previously closed at $3.55.
Lakeshore Biopharma Stock Down 1.4 %
The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 0.17. The stock has a 50 day moving average of $2.79.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC bought a new stake in Lakeshore Biopharma during the third quarter valued at approximately $169,000. Hhlr Advisors LTD. purchased a new position in shares of Lakeshore Biopharma during the 3rd quarter valued at about $513,000. Finally, FMR LLC bought a new stake in Lakeshore Biopharma in the 3rd quarter worth approximately $803,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.
About Lakeshore Biopharma
LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Featured Articles
- Five stocks we like better than Lakeshore Biopharma
- What Are Some of the Best Large-Cap Stocks to Buy?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Using the MarketBeat Dividend Yield Calculator
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Quiet Period Expirations Explained
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.